Tango Therapeutics’ IND application for TNG260 receives FDA clearance
2023-04-03
临床申请免疫疗法临床研究
Preview
来源: Pharmaceutical Technology
TNG260 is a novel, selective inhibitor of the CoREST complex. Credit: Myriams-Fotos from Pixabay.
Tango Therapeutics has received clearance from the US Food and Drug Administration (FDA) for its investigational new drug (IND) application for TNG260 to treat STK11-mutant cancers.
TNG26 is a first-in-class inhibitor of the CoREST complex (co-repressor of repressor element-1 silencing transcription). It is in preclinical development to reverse immune evasion in STK11 mutated cancersSTK11 mutated cancers.
Tango Therapeutics president and CEO Dr Barbara Weber said: “FDA clearance of our IND application to initiate the TNG260 phase 1/2 trial is an important milestone in the development of this novel treatment for STK11-mutant cancers. STK11 mutations drive resistance to standard of care immunotherapy, and are a major challenge in treating many cancers, including non-small cell lung cancer.
“We expect that TNG260 will be among the first oncology molecules to leverage the benefits of genetically-based patient selection (STK11-mutation) with checkpoint inhibitor therapy. We look forward to initiating the Phase 1/2 clinical trial of TNG260 in the second half of 2023.”
The safety, pharmacokinetics, pharmacodynamics and efficacy of TNG260, in combination with pembrolizumab, will be assessed in the phase 1/2 clinical study.
The study will cover patients with locally advanced or metastatic cancer, or any solid tumour with an STK11 loss-of-function mutation.
The company stated that the combination of TNG260 with an anti-PD-1 antibody enabled sustained complete tumour regressions in syngeneic models with an STK11 mutation and an intact immune system.
The combination also induced immune memory, which prevented re-implantation of the same tumour xenograft.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
靶点
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。